Short: From Obesity Drug to Risk Strategy - Why Captives Need to Rethink GLP-1s

In this GCP Short, produced in partnership with MAXIS Global Benefits Network, we explore findings from the network's latest whitepaper on GLP-1s, often known as weight-loss drugs.

Dr Leena Johns, chief health & wellness officer at MAXIS GBN and author of the whitepaper, joins Richard to discuss the evolving demand and understanding of GLP-1s and why captives are perfectly suited to support employer's in implementing a global GLP-1 strategy.

Read the full whitepaper here.

More information and register for Global Benefits Congress, in London, on 22 October, here.